Latest research on Erbitux

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Erbitux interactions

Currently, the standard of care (category 1 evidence) for recurrent/metastatic SCCHN is the regimen used in the EXTREME study (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer), consisting of cetuximab in combination with Cisplatin or Carboplatin plus 5-Fluorouracil (5-FU) [2, 3]. [source, 2016]
Cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix) were purchased from Merck (Whitehouse Station, NJ), Roche (Basel, Switzerland), and Amgen (Thousand Oaks, CA), respectively. [source, 2016]
The conjugation efficiency between bispecific antibody (Bis), Herceptin (Her), Erbitux (Erb), and both Herceptin and Erbitux (Erb+Her) with MnMEIO-CyTE777-mPEG NPs was determined by collecting unconjugated antibodies in the supernatant after centrifugal filtration of the antibody reaction mixture and measuring the concentration using NanoDrop ND-1000 UV-vis spectrometer. [source, 2016]
The variable domains of heavy (VH) and light (VL) chains of anti-EGFR (Erbitux) and anti-HER2/neu (Herceptin) were linked via (Gly4Ser)3 to form scFv (Erbitux) and scFv (Herceptin), respectively. [source, 2016]
The bispecific fragment was then generated by linking scFv (Erbitux) and scFv (Herceptin) with a flexible peptide linker, ASTGS, and cloned into the 5' region of the human IgG1 Fc in pFUSE-hIgG1e4-Fc vector to form an Fc-fusion construct (Fig. 1A). [source, 2016]
Tumor cells pretreated with excess Herceptin, Erbitux, and both antibodies, respectively, for 1 hr at 37 °C, followed by incubation with MnMEIO-CyTE777-(Bis)-mPEG NPs. [source, 2016]
Gefitinib (Iressa, AstraZeneca), a small reversible EGFR inhibitor, and IMC-C225 (Erbitux, ImClone Systems), an inhibitory anti-EGFR monoclonal antibody, have been approved for non small-cell lung and metastatic colorectal cancer treatment, respectively. [source, 2015]
The search for unpublished RCTs or those in progress was from their metaRegister of Controlled Trials [38] using the following search terms: monoclonal antibodies; mAb; anti-VEGF; anti-EGRF; bevacizumab OR, Avastin OR. panitumumab OR. Vectibix cetuximab OR. Erbitux OR. colorectal neoplasms OR. colorectal cancer OR. colorectal carcinomas. [source, 2015]
In the Study of Chemoradiotherapy in OesoPhageal cancer with Erbitux (SCOPE) 1 trial, outcome of definitive CRT with or that without the addition of cetuximab to CDDP and 5-FU in patients with esophageal cancer were compared [24]. [source, 2015]
In 2004, the EGFR inhibitor cetuximab (Erbitux) was approved in the US for the second-line treatment of mCRC in patients whose tumors overexpress EGFR [6], and in 2006, the EGFR inhibitor panitumumab (Vectibix) was approved for the second-line treatment of mCRC in patients with disease progression on or following conventional chemotherapies [7]. [source, 2015]